phase 3... stand alone trial has always been on the cards.
accelerated approval has always been on the cards.
neither have changed except we are moving forward without dilution nor partners (currently) to share the spoils with. that's all we know at this moment in time. Directions change to the best path forward at the time depending on the set of circumstances. To get upset about this company not bringing a drug to market ten years ago plays into the biotech success statistics that are easily found and constantly proven. I see this as no different, except that our odds of winning now, a this point are much higher.
- Forums
- ASX - By Stock
- PER
- Ann: ATL1102 Revised Plans accelerate reporting of unblinded data
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-60
-
- There are more pages in this discussion • 292 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.0¢ |
Change
-0.001(1.23%) |
Mkt cap ! $72.12M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.0¢ | $63.52K | 777.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 97561 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43377 | 0.080 |
2 | 212658 | 0.078 |
1 | 200000 | 0.077 |
3 | 91500 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 97561 | 1 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 141000 | 2 |
0.086 | 106100 | 2 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
PER (ASX) Chart |